{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:17:18Z","timestamp":1775326638276,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>TL-895 (formerly known as M7583) is a potent, highly selective, adenosine triphosphate (ATP)-competitive, second-generation, irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK). We characterized its biochemical and cellular effects in in vitro and in vivo models. TL-895 was evaluated preclinically for potency against BTK using IC<jats:sub>50<\/jats:sub> concentration\u2013response curves; selectivity using a 270-kinase panel; BTK phosphorylation in Ramos Burkitt\u2019s lymphoma cells by ProteinSimple Wes analysis of one study; anti-proliferative effects in primary chronic lymphocytic leukemia (CLL) blasts; cell viability effects in diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) cell lines; effects on antibody-dependent cell-mediated cytotoxicity (ADCC) from Daudi cells and chromium-51 release from human tumor cell lines; and efficacy in vivo using four MCL xenograft model and 21 DLBCL patient-derived xenograft (PDX) models (subtypes: 9 ABC, 11 GCB, 1 Unclassified). TL-895 was active against recombinant BTK (average IC<jats:sub>50<\/jats:sub> 1.5\u00a0nM) and inhibited only three additional kinases with IC<jats:sub>50<\/jats:sub> within tenfold of BTK activity. TL-895 inhibited BTK auto-phosphorylation at the Y223 phosphorylation site (IC<jats:sub>50<\/jats:sub> 1\u201310\u00a0nM). TL-895 inhibited the proliferation of primary CLL blasts in vitro and inhibited growth in a subset of activated DLBCL and MCL cell lines. TL-895 inhibited the ADCC mechanism of therapeutic antibodies only at supra-clinical exposure levels. TL-895 significantly inhibited tumor growth in the Mino MCL xenograft model and in 5\/21 DLBCL PDX models relative to vehicle controls. These findings demonstrate the potency of TL-895 for BTK and its efficacy in models of B-cell lymphoma despite its refined selectivity.<\/jats:p>","DOI":"10.1038\/s41598-023-47735-z","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:03:09Z","timestamp":1700600589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-8479","authenticated-orcid":false,"given":"Samantha M.","family":"Goodstal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Crandall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albertina","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Soloviev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riham","family":"Iadevaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven-Eric","family":"Schelhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anderson","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"47735_CR1","unstructured":"Food and Drug Administration. Imbruvica\u00ae (ibrutinib) Prescribing Information 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205552s007lbl.pdf"},{"key":"47735_CR2","unstructured":"European Medicines Agency. Imbruvica\u00ae (ibrutinib) Summary of Product Characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf"},{"issue":"3","key":"47735_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371(3), 213\u2013223 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"47735_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"47735_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 372(15), 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"47735_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21(8), 922\u2013926 (2015).","journal-title":"Nat. Med."},{"issue":"3","key":"47735_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.15108","volume":"181","author":"O Hershkovitz-Rokah","year":"2018","unstructured":"Hershkovitz-Rokah, O., Pulver, D., Lenz, G. & Shpilberg, O. Ibrutinib resistance in mantle cell lymphoma: Clinical, molecular and treatment aspects. Br. J. Haematol. 181(3), 306\u2013319 (2018).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"47735_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Liu, C., Tsui, S. T. & Liu, D. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9(1), 80 (2016).","journal-title":"J. Hematol. Oncol."},{"issue":"10121","key":"47735_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet (London, England). 391(10121), 659\u2013667 (2018).","journal-title":"Lancet (London, England)."},{"issue":"2","key":"47735_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf, T. et al. Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J. Pharmacol. Exp. Ther. 363(2), 240\u2013252 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"47735_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Zhang, M. & Liu, D. Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor. J. Hematol. Oncol. 9, 21 (2016).","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"47735_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel, V. K. et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: Similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32(4), 920\u2013930 (2018).","journal-title":"Leukemia"},{"issue":"26","key":"47735_CR13","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","volume":"1","author":"AP Bye","year":"2017","unstructured":"Bye, A. P. et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 1(26), 2610\u20132623 (2017).","journal-title":"Blood Adv."},{"key":"47735_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clim.2016.01.012","volume":"164","author":"AT Bender","year":"2016","unstructured":"Bender, A. T. et al. Btk inhibition treats TLR7\/IFN driven murine lupus. Clin. Immunol. 164, 65\u201377 (2016).","journal-title":"Clin. Immunol."},{"issue":"1","key":"47735_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88\u201394 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"47735_CR16","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","volume":"20","author":"AF Herrera","year":"2014","unstructured":"Herrera, A. F. & Jacobsen, E. D. Ibrutinib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 20(21), 5365\u20135371 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"47735_CR17","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U.S.A. 107(29), 13075\u201313080 (2010).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"47735_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd, J. C. et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374(4), 323\u2013332 (2016).","journal-title":"N. Engl. J. Med."},{"key":"47735_CR19","unstructured":"Food and Drug Administration. Highlights of prescribing information: CALQUENCE (acalabrutinib) 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf"},{"issue":"Suppl 1","key":"47735_CR20","first-page":"Abstract 3845","volume":"130","author":"W Jurczak","year":"2017","unstructured":"Jurczak, W. et al. First in human, Phase I\/II trial of the Bruton\u2019s tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies: Study design and initial outcomes. Blood 130(Suppl 1), Abstract 3845 (2017).","journal-title":"Blood"},{"issue":"14","key":"47735_CR21","first-page":"1754","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics (Oxford, England) 25(14), 1754\u20131760 (2009).","journal-title":"Bioinformatics (Oxford, England)"},{"key":"47735_CR22","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.12688\/f1000research.10082.1","volume":"5","author":"MJ Ahdesmaki","year":"2016","unstructured":"Ahdesmaki, M. J., Gray, S. R., Johnson, J. H. & Lai, Z. Disambiguate: An open-source application for disambiguating two species in next generation sequencing data from grafted samples. F1000Research 5, 2741 (2016).","journal-title":"F1000Research"},{"key":"47735_CR23","doi-asserted-by":"crossref","unstructured":"Salm, M., Schelhorn, S.-E., Lancashire, L. & Grombacher, T. pdxBlacklist: Identifying artefactual variants in patient-derived xenograft samples. bioRxiv (2017).","DOI":"10.1101\/180752"},{"issue":"4","key":"47735_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12(4), e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"47735_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6(2), 80\u201392 (2012).","journal-title":"Fly"},{"issue":"D1","key":"47735_CR26","doi-asserted-by":"publisher","first-page":"D840","DOI":"10.1093\/nar\/gkw971","volume":"45","author":"KJ Karczewski","year":"2017","unstructured":"Karczewski, K. J. et al. The ExAC browser: Displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 45(D1), D840\u2013D845 (2017).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"47735_CR27","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46(D1), D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"47735_CR28","doi-asserted-by":"crossref","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides accurate, fast, and bias-aware transcript expression estimates using dual-phase inference. bioRxiv (2016).","DOI":"10.1101\/021592"},{"issue":"16","key":"47735_CR29","first-page":"2078","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics (Oxford, England) 25(16), 2078\u20132079 (2009).","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"20","key":"47735_CR30","first-page":"2678","volume":"28","author":"F Garcia-Alcalde","year":"2012","unstructured":"Garcia-Alcalde, F. et al. Qualimap: Evaluating next-generation sequencing alignment data. Bioinformatics (Oxford, England) 28(20), 2678\u20132679 (2012).","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"21","key":"47735_CR31","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","volume":"94","author":"MI Wahl","year":"1997","unstructured":"Wahl, M. I. et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton\u2019s tyrosine kinase via alternative receptors. Proc. Natl. Acad. Sci. USA 94(21), 11526\u201311533 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15_suppl","key":"47735_CR32","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1200\/JCO.2018.36.15_suppl.7547","volume":"36","author":"MJ Dyer","year":"2018","unstructured":"Dyer, M. J. et al. Acalabrutinib monotherapy in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 36(15_suppl), 7547 (2018).","journal-title":"J. Clin. Oncol."},{"key":"47735_CR33","doi-asserted-by":"crossref","unstructured":"Jurczak, W., Rule, S., Townsend, W., Tucker, D., Sarholz, B., Scheele, J. et al. A Phase I\/II, first in human trial of the Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Presented at American Hematology Society, San Diego, 2018, Poster number 4161.","DOI":"10.1182\/blood-2018-99-112808"},{"issue":"16","key":"47735_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","volume":"131","author":"CS Sauter","year":"2018","unstructured":"Sauter, C. S. et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 131(16), 1805\u20131808 (2018).","journal-title":"Blood"},{"key":"47735_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-019-0141-1","volume":"8","author":"A Albertsson-Lindblad","year":"2019","unstructured":"Albertsson-Lindblad, A., Freiburghaus, C., Jerkeman, M. & Ek, S. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Exp. Hematol. Oncol. 8, 16 (2019).","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"47735_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2014.107011","volume":"100","author":"F Da Roit","year":"2015","unstructured":"Da Roit, F. et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: Implications for combination therapy. Haematologica 100(1), 77\u201386 (2015).","journal-title":"Haematologica"},{"issue":"12","key":"47735_CR37","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt, H. E. et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 123(12), 1957\u20131960 (2014).","journal-title":"Blood"},{"issue":"1","key":"47735_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong, D. P. et al. The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis. Blood 128(1), 138\u2013140 (2016).","journal-title":"Blood"},{"issue":"7","key":"47735_CR39","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.3324\/haematol.2015.140806","volume":"101","author":"JR Brown","year":"2016","unstructured":"Brown, J. R. et al. Phase I study of single-agent CC-292, a highly selective Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory chronic lymphocytic leukemia. Haematologica 101(7), e295\u2013e298 (2016).","journal-title":"Haematologica"},{"issue":"4","key":"47735_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter, H. S. et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127(4), 411\u2013419 (2016).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47735-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:23:07Z","timestamp":1700644987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47735"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47735-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMG, JM, JL, TC, LC, ATB, AP, MS, JSW, RI, FM, and AC are, or were, employees of EMD Serono Research and Development Institute (a business of Merck KGaA, Darmstadt, Germany). SES and ER are employees of Merck KGaA, Darmstadt, Germany. The authors declare no other potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20412"}}